Akari Therapeutics (AKTX) Research & Development (2014 - 2026)
Akari Therapeutics (AKTX) reported Research & Development of $1.5 million for Q1 2026, up 79.46% on a YoY basis from $813000.0 in Q1 2025, and up 34.35% sequentially from $1.1 million in Q4 2025.
Akari Therapeutics (AKTX) Research & Development (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 9 years of Research & Development data on file, last reported at $1.5 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 79.46% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (down 69.9% YoY), and the FY2025 full-year result was $2.8 million, down 59.69% from the prior year.
- Research & Development climbed to $1.5 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $7.2 million in Q4 2024 to a low of -$314000.0 in Q3 2023.
- A 4-year average of $1.7 million and a median of $1.5 million in 2026 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 188.16% in 2024 and sank 84.98% in 2025, its largest moves.
- Tracing AKTX's Research & Development over 4 years: stood at $2.5 million in 2023, then jumped by 188.16% to $7.2 million in 2024, then slumped by 84.98% to $1.1 million in 2025, then jumped by 34.35% to $1.5 million in 2026.
- Business Quant data shows AKTX's Research & Development at $1.5 million in Q1 2026, $1.1 million in Q4 2025, and $249000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 364.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 249,000.00 |
| Jun 30, 2025 | 667,000.00 |
| Mar 31, 2025 | 813,000.00 |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 143,000.00 |
| Jun 30, 2024 | 3.31 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | -314,000.00 |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 1.73 Mn |
| Dec 31, 2020 | 4.66 Mn |
| Sep 30, 2020 | -1.59 Mn |
| Jun 30, 2020 | 3.02 Mn |
| Mar 31, 2020 | 2.73 Mn |
| Dec 31, 2019 | 5.70 Mn |
| Sep 30, 2019 | 1.76 Mn |
| Jun 30, 2019 | 3.59 Mn |